Phoenix Tissue Repair, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05143190
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04599881
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase 1
Completed
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Drug: Normal saline
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03752905
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Thomas Jefferson Univeristiy, Philadelphia, Pennsylvania, United States
News
No news found